Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(4):257; doi:10.1093/jnci/djk102
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Savage, L.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

MEMO TO THE MEDIA

Press Release

Tamoxifen Yields Long-Term Reduction in Breast Cancer Risk

Liz Savage

jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

Tamoxifen offers long-term benefits for breast cancer prevention among women at high risk of the disease, according to two randomized, blinded clinical trials in the February 21 Journal of the National Cancer Institute. The trials found that the breast cancer risk reduction persists long after women stop taking tamoxifen.

Tamoxifen is used both to treat breast cancer and to prevent it among women at high risk of breast cancer. However, most of the data on tamoxifen for breast cancer prevention comes from the period when women were . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Tamoxifen: An Enduring Star
Umberto Veronesi, Patrick Maisonneuve, and Andrea Decensi
J Natl Cancer Inst 2007 99: 258-260. [Extract] [Full Text] [PDF]

Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer—96-Month Follow-up of the Randomized IBIS-I Trial
Jack Cuzick, John F. Forbes, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, and Anthony Howell
J Natl Cancer Inst 2007 99: 272-282. [Abstract] [Full Text] [PDF]

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial
Trevor J. Powles, Sue Ashley, Alwynne Tidy, Ian E. Smith, and Mitch Dowsett
J Natl Cancer Inst 2007 99: 283-290. [Abstract] [Full Text] [PDF]